An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

Gynecologic Oncology

Volumn 124, Issue 1, 2012, Pages 10-14

  Chi, Dennis S ^a   Musa, Fernanda ^b   Dao, Fanny ^a   Zivanovic, Oliver ^a   Sonoda, Yukio ^a   Leitao, Mario M ^a   Levine, Douglas A ^a   Gardner, Ginger J ^a   Abu Rustum, Nadeem R ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Cytoreduction; Fallopian tube cancer; Neoadjuvant chemotherapy; Ovarian cancer; Primary debulking surgery; Primary peritoneal cancer

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ANALYSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EPITHELIAL OVARIAN CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIMARY DEBULKING SURGERY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 83055181259     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.08.014     Document Type: Article

References (27)

1. Cancer facts & figures 2010 American Cancer Society
2. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, and M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979 [discussion 979-80]
3. D.S. Chi, E.L. Eisenhauer, J. Lang, J. Huh, L. Haddad, and N.R. Abu-Rustum What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103 2006 559 564 (Pubitemid 44602167)
4. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Gynecologic oncology group. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627 (Pubitemid 47372600)
5. I. Vergote, C.G. Tropé, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
6. W.J. Hoskins, B.N. Bundy, J.T. Thigpen, and G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 1992 159 166 (Pubitemid 23001322)
7. Staging announcements: FIGO cancer committee Gynecol Oncol 25 1986 383 385
8. R.C. Martin II, M.F. Brennan, and D.P. Jaques Quality of complication reporting in the surgical literature Ann Surg 235 2002 803 813 (Pubitemid 34547298)
9. D.S. Chi, C.C. Franklin, D.A. Levine, F. Akselrod, P. Sabbatini, and W.R. Jarnagin Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach Gynecol Oncol 94 2004 650 654 (Pubitemid 39194456)
10. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
11. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 2001 4054 4057 (Pubitemid 32976692)
12. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
13. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1996 163 170
14. C.T. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 42 1975 101 104
15. H.E. Skipper Adjuvant chemotherapy Cancer 41 1978 936 940 (Pubitemid 8313230)
16. J.H. Goldie, and A.J. Coldman A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat Rep 63 1979 1727 1733 (Pubitemid 10138923)
17. D.S. Chi, E.L. Eisenhauer, O. Zivanovic, Y. Sonoda, N.R. Abu-Rustum, and D.A. Levine Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm Gynecol Oncol 114 2009 26 31
18. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259 (Pubitemid 34177431)
19. G.D. Aletti, S.C. Dowdy, B.S. Gostout, M.B. Jones, C.R. Stanhope, and T.O. Wilson Aggressive surgical effort and improved survival in advanced-stage ovarian cancer Obstet Gynecol 107 2006 77 85
20. S.M. Eisenkop, and N.M. Spirtos Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 82 2001 435 441 (Pubitemid 32826441)
21. M.C. Lim, S. Kang, Y.J. Song, S.H. Park, and S.Y. Park Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer J Korean Med Sci 25 2010 1034 1040
22. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
23. D.S. Chi, O. Zivanovic, K.L. Levinson, V. Kolev, J. Huh, and J. Dottino The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas Gynecol Oncol 119 2010 38 42
24. J.Y. Park, S.S. Seo, S. Kang, K.B. Lee, S.Y. Lim, and H.S. Choi The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns Gynecol Oncol 103 2006 977 984 (Pubitemid 44834356)
25. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 2006 1070 1076 (Pubitemid 44821335)
26. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
27. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, and M. Friedlander Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup J Clin Oncol 27 2009 1419 1425